Merck & Co Inc (MRK)
102.95
-1.35
(-1.29%)
USD |
NYSE |
Sep 29, 16:00
103.02
+0.07
(+0.07%)
Pre-Market: 20:00
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 261.24B |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | 22.05% |
Valuation | |
PE Ratio | 84.39 |
PE Ratio (Forward) | Upgrade |
PS Ratio | 4.493 |
Price to Book Value | 6.752 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | 0.73 |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 0.9539 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 27.26% |
Profile
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States. |
URL | https://www.merck.com |
Investor Relations URL | https://www.merck.com/investor-relations |
HQ State/Province | New Jersey |
Sector | Healthcare |
Industry | Drug Manufacturers - General |
Equity Style | Large Cap/Blend |
Next Earnings Release | Oct. 27, 2023 (est.) |
Last Earnings Release | Aug. 01, 2023 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | Sep. 14, 2023 |
Ratings
Profile
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States. |
URL | https://www.merck.com |
Investor Relations URL | https://www.merck.com/investor-relations |
HQ State/Province | New Jersey |
Sector | Healthcare |
Industry | Drug Manufacturers - General |
Equity Style | Large Cap/Blend |
Next Earnings Release | Oct. 27, 2023 (est.) |
Last Earnings Release | Aug. 01, 2023 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | Sep. 14, 2023 |